Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ViewRay Inc is a medical devices business based in the US. ViewRay shares (VRAY) are listed on the NASDAQ and all prices are listed in US Dollars. ViewRay employs 236 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $4.45 |
|---|---|
| 52-week range | $3.79 - $8.25 |
| 50-day moving average | $5.58 |
| 200-day moving average | $5.88 |
| Wall St. target price | $8.57 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.45 from 2022-01-21
| 1 week (2022-01-14) | -6.71% |
|---|---|
| 1 month (2021-12-23) | -18.50% |
| 3 months (2021-10-22) | -34.65% |
| 6 months (2021-07-23) | -31.11% |
| 1 year (2021-01-22) | -0.67% |
|---|---|
| 2 years (2020-01-24) | 40.38% |
| 3 years (2019-01-24) | 7.54 |
| 5 years (2017-01-24) | 5.3 |
| Revenue TTM | $68.2 million |
|---|---|
| Gross profit TTM | $-4,059,000 |
| Return on assets TTM | -22.67% |
| Return on equity TTM | -81.17% |
| Profit margin | -159.97% |
| Book value | $0.72 |
| Market capitalisation | $845.4 million |
TTM: trailing 12 months
We're not expecting ViewRay to pay a dividend over the next 12 months.
ViewRay's shares were split on a 683:576 basis on 7 July 2015. So if you had owned 576 shares the day before before the split, the next day you'd have owned 683 shares. This wouldn't directly have changed the overall worth of your ViewRay shares – just the quantity. However, indirectly, the new 15.7% lower share price could have impacted the market appetite for ViewRay shares which in turn could have impacted ViewRay's share price.
Over the last 12 months, ViewRay's shares have ranged in value from as little as $3.785 up to $8.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ViewRay's is 0.7881. This would suggest that ViewRay's shares are less volatile than average (for this exchange).
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.